Memantine (hydrochloride) – 25 mg

Brand:
Cayman
CAS:
41100-52-1
Storage:
22
UN-No:
Non-Hazardous - /

Memantine is an NMDA receptor antagonist that blocks NMDA-induced currents in rat retinal ganglion cells by 90% when used at a concentration of 12 μM.{22399} It reverses inhibition of dephosphorylation of the synthetic tau phosphopeptide p17 (tau194-207) induced by the endogenous inhibitor of protein phosphatase 2A (PP2A) I1PP2A in vitro.{41954} In vivo, memantine (2 mg/kg) restores PP2A activity, decreases GSK-3β and amyloid-β (Aβ) levels in the hippocampus, cerebral cortex, and ventricular areas, and attenuates spatial learning and memory in the AAV1-I1PP2A rat model of Alzheimer’s disease. Memantine (20 mg/kg) reduces responding on the ethanol-associated lever in a cue-induced ethanol-seeking test in rats.{41955} It also decreases secretion of matrix metalloproteinase-9 (MMP-9), degradation of collagen IV, the size of cerebral ischemia-induced brain infarcts, and neuronal cell death in a mouse model of focal cerebral ischemia.{41956}  

 

SKU: - Category:

Description

An NMDA receptor antagonist; blocks NMDA-induced currents in rat retinal ganglion cells by 90% at 12 μM; reverses I1PP2A-induced inhibition of dephosphorylation of tau194-207 in vitro; restores PP2A activity, decreases GSK-3β and Aβ levels in the hippocampus, cerebral cortex, and ventricular areas, and attenuates spatial learning and memory in the AAV1-I1PP2A rat model of Alzheimer’s disease at 2 mg/kg; reduces responding on the ethanol-associated lever in a cue-induced ethanol seeking test in rats at 20 mg/kg; decreases secretion of MMP-9, degradation of collagen IV, the size of cerebral ischemia-induced brain infarcts, and neuronal cell death in a mouse model of focal cerebral ischemia,


Formal name: 3,5-dimethyl-tricyclo[3.3.1.13,7]decan-1-amine, monohydrochloride

Synonyms:  Akatinol|Axura|Ebix|Namenda|NSC 102290|SUN Y7017

Molecular weight: 215.8

CAS: 41100-52-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Ion Channel Modulation|Blockers||Research Area|Neuroscience|Behavioral Neuroscience|Addiction Research||Research Area|Neuroscience|Behavioral Neuroscience|Learning & Memory||Research Area|Neuroscience|Neurodegenerative Disorders|Alzheimer’s Disease||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease||Research Area|Neuroscience|Neuroprotection|Ischemia||Research Area|Neuroscience|Seizure Disorders